PubHawk
JCO Precis Oncol March 2023 PMID 36926986

Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.

Katherine I Zhou, Vishal Vashistha, Aixia Guo, Sara Ahmed, Michael J Kelley

Full text PDF Download social card

Mentions

39
Peak: 24 in Mar 2023
across 2 sources since Mar 2023

Extended reach

192,433
potential audience

Total likes

97

Video views

15

Mentions per month

Mar 2023 – Apr 2024

Where it's discussed

  • X / Twitter38 posts
  • YouTube1 videos

AI synopsis

What people are saying

Several discussions emphasize the discrepancy between clinical trial successes and real-world outcomes, with phrases like 'no responses seen' and 'disappointing outcomes' illustrating skepticism about TRK inhibitors' effectiveness. The tone is somewhat critical and analytical, reflecting a cautious stance on the current utility of these therapies outside controlled environments.

AgreementLow agreement

Most discussions express skepticism or highlight disappointing results, indicating a lack of strong support for the effectiveness of TRK inhibitors in real-world settings.

InterestModerate interest

Discussions show curiosity about real-world outcomes and the challenges faced, demonstrating moderate interest.

EngagementModerate engagement

Many posts reference specific data points, such as the 0% response rate and the number of patients involved, showing some depth of engagement.

ImpactLow impact

Overall, the tone suggests that the publication may have a limited immediate impact on clinical practice, emphasizing the gap between clinical trial success and real-world results.

Abstract in brief

  • Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are associated with various tumors, but this study examines the real-world effectiveness of TRK inhibitors in Veterans Health Administration patients.
  • Out of 33 identified patients with NTRK fusions, only 12 received TRK inhibitors, and none showed objective responses to the treatment; eight experienced significant side effects.
  • This research indicates that the real-world experience with TRK inhibitors is less optimistic than clinical trials, emphasizing the need for further studies in diverse populations to better understand these therapies.
Read the full abstract

Top posts

Most liked on X and Bluesky
Stephen V Liu, MD
@StephenVLiu · X

Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated with NTRK inhibitors - no responses seen. Included some non-canonical fusions and some did achieve durable SD but disappointing outcomes. https://t.co/B31SCHTzcx

Mar 17, 2023 · 27 likes · 8 shares · 28,673 followers View post →
Michael Kelley, MD
@kelleymic · X

NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3 https://t.co/V0ToSugT1M

Jun 24, 2023 · 22 likes · 10 shares · 239 followers View post →
H. Jack West, MD, FASCO
@JackWestMD · X

@VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even tho we do it, practice is still driven overwhelmingly by hype, anecdotes, & faith-based bias rather than real evidence. This is what you see in real world: https://t.co/qdAg0mne4B

Mar 19, 2023 · 20 likes · 5 shares · 22,392 followers View post →
レ点
@m0370 · X

ガッカリ大賞？NTRK fusion/rearrangementの退役軍人リアルワールドデータ。陽性率が固形がんの0.12%と既報よりずっと低い上に、12例のTRK阻害剤が投与されたが奏効は0例（えっ！？）で8例が毒性中止。がんゲノム界隈では待望の治療標的だったはずなのに…／JCOPO https://t.co/IoQ2yWLPjI

Mar 23, 2023 · 12 likes · 28,888 followers View post →
Ben Westphalen
@BenWestphalen · X

Puzzling: A cohort of #cancer #patients w NTRK-fusion ✅ disease from the @DeptVetAffairs #PrecisionOncology program in @JCOPO_ASCO 33 patients

Mar 23, 2023 · 7 likes · 4 shares · 5,044 followers View post →
Mike Thompson, MD, PhD, FASCO
@mtmdphd · X

Real-world Experience With Neurotrophic Tyrosine Receptor Kinase [NTRK] Fusion–positive Tumors and Tropomyosin Receptor Kinase [TRK] Inhibitors in Veterans [Mar 16, 2023] Zhou et al. @JCOPO_ASCO https://t.co/U9nnAXRj0n #PrecisionMedicine #NTRK HT @BenWestphalen https://t.co/vBbenudQhV

Mar 24, 2023 · 3 likes · 1 share · 22,990 followers View post →

All mentions

Sushma Jonna
@SushmaJonna · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 27, 2023 · 10 shares · 276 followers View post →
Ramy Sedhom, MD, FASCO
@ramsedhom · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 2,278 followers View post →
Sheyda Abdullaeva
@SheydaDoc · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 108 followers View post →
Madison Conces, MD
@MadisonConces · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 1,070 followers View post →
Devika Das, MD, MSHQS, FASCO
@DevikaDasMD · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 5,717 followers View post →
sunlight
@EllaJones1994 · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 1,209 followers View post →
Vladmir C. Cordeiro de Lima, MD, PhD
@ClaudioVladmir · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 1,221 followers View post →
Timothée Olivier, MD
@Timothee_MD · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 2,690 followers View post →
Alfredo Addeo MD
@Alfdoc2 · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 2,867 followers View post →
Santhosh Ambika
@RenoHemonc · X

RT @kelleymic: NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3

Jun 26, 2023 · 10 shares · 4,046 followers View post →
Michael Kelley, MD
@kelleymic · X

NTRK inhibitors in real world data. RR=0%. https://t.co/Pao6LOIKWV @KatherineZhouMD @VeteransHealth https://t.co/oGVInRi3m3 https://t.co/V0ToSugT1M

Jun 24, 2023 · 22 likes · 10 shares · 239 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

.@KatherineZhouMD et al. describe a real-world population from Veterans Affairs (VA) National Precision Oncology Program, where the prevalence of NTRK rearrangements was lower than in clinical trials & TRK inhibitors did not lead to any objective responses https://t.co/ip0b3vefwe https://t.co/uhe8lzmuZR

Apr 16, 2023 · 5,311 followers View post →
PRECISION ONCOLOGY CONNECT
@PresOnc_Connect · X

Latest information from #JCOPO on real world experience with #NTRK tumours and #TRK inhibitors @KatherineZhouMD #MedEd https://t.co/bQNW4YRYLg https://t.co/yEm8WkKloZ https://t.co/oLAbP0xzvz

Apr 4, 2023 · 1 like · 1,601 followers View post →
Pakistan Society Of Clinical Oncology
@PSCOhandle · X

RT @JCOPO_ASCO:

Apr 2, 2023 · 2 shares · 85 followers View post →
Chenyu Lin, MD
@ChenyuLinMD · X

New national @DeptVetAffairs study on real world outcomes of TRK inhibitors, out in @JCOPO_ASCO led by @KatherineZhouMD & @kelleymic. ORR of 0%, many AEs, still a great challenge to reproduce the success seen in clinical trials. @VAResearch @DukeCancer ➡️https://t.co/iLsPFSToml https://t.co/F4lQZ6JV2p

Mar 31, 2023 · 2 likes · 576 followers View post →
Angelo Dipasquale
@AngeloDipa_ · X

RT @JCOPO_ASCO:

Mar 31, 2023 · 2 shares · 1,622 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

Mar 31, 2023 · 3 likes · 2 shares · 5,311 followers View post →
CancerLinks 
@CancerLinks · X

RT @BenWestphalen: Puzzling: A cohort of #cancer #patients w NTRK-fusion ✅ disease from the @DeptVetAffairs #PrecisionOncology program in @…

Mar 27, 2023 · 4 shares · 97 followers View post →
Ben Westphalen
@BenWestphalen · X

RT @mtmdphd: Real-world Experience With Neurotrophic Tyrosine Receptor Kinase [NTRK] Fusion–positive Tumors and Tropomyosin Receptor Kinase…

Mar 24, 2023 · 1 share · 5,044 followers View post →
Mike Thompson, MD, PhD, FASCO
@mtmdphd · X

Real-world Experience With Neurotrophic Tyrosine Receptor Kinase [NTRK] Fusion–positive Tumors and Tropomyosin Receptor Kinase [TRK] Inhibitors in Veterans [Mar 16, 2023] Zhou et al. @JCOPO_ASCO https://t.co/U9nnAXRj0n #PrecisionMedicine #NTRK HT @BenWestphalen https://t.co/vBbenudQhV

Mar 24, 2023 · 3 likes · 1 share · 22,990 followers View post →
Hanne Hamre
@hanne_hamre · X

RT @BenWestphalen: Puzzling: A cohort of #cancer #patients w NTRK-fusion ✅ disease from the @DeptVetAffairs #PrecisionOncology program in @…

Mar 23, 2023 · 4 shares · 125 followers View post →
レ点
@m0370 · X

ガッカリ大賞？NTRK fusion/rearrangementの退役軍人リアルワールドデータ。陽性率が固形がんの0.12%と既報よりずっと低い上に、12例のTRK阻害剤が投与されたが奏効は0例（えっ！？）で8例が毒性中止。がんゲノム界隈では待望の治療標的だったはずなのに…／JCOPO https://t.co/IoQ2yWLPjI

Mar 23, 2023 · 12 likes · 28,888 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

RT @BenWestphalen: Puzzling: A cohort of #cancer #patients w NTRK-fusion ✅ disease from the @DeptVetAffairs #PrecisionOncology program in @…

Mar 23, 2023 · 4 shares · 5,311 followers View post →
CancerLinks 
@CancerLinks · X

RT @BenWestphalen: Puzzling: A cohort of #cancer #patients w NTRK-fusion ✅ disease from the @DeptVetAffairs #PrecisionOncology program in @…

Mar 23, 2023 · 4 shares · 97 followers View post →
Ben Westphalen
@BenWestphalen · X

Puzzling: A cohort of #cancer #patients w NTRK-fusion ✅ disease from the @DeptVetAffairs #PrecisionOncology program in @JCOPO_ASCO 33 patients

Mar 23, 2023 · 7 likes · 4 shares · 5,044 followers View post →
Apar Kishor Ganti
@AparGanti · X

RT @JackWestMD: @VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even t…

Mar 20, 2023 · 5 shares · 259 followers View post →
denis Moro-Sibilot
@DMSLung · X

RT @JackWestMD: @VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even t…

Mar 20, 2023 · 5 shares · 1,270 followers View post →
JCO Precision Oncology
@JCOPO_ASCO · X

RT @StephenVLiu: Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated wit…

Mar 20, 2023 · 8 shares · 5,311 followers View post →
Vladmir C. Cordeiro de Lima, MD, PhD
@ClaudioVladmir · X

RT @JackWestMD: @VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even t…

Mar 19, 2023 · 5 shares · 1,221 followers View post →
bhawna sirohi
@SirohiBhawna · X

RT @JackWestMD: @VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even t…

Mar 19, 2023 · 5 shares · 5,154 followers View post →
Luis Eduardo Pino V
@docpinoAI · X

RT @JackWestMD: @VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even t…

Mar 19, 2023 · 5 shares · 5,825 followers View post →
H. Jack West, MD, FASCO
@JackWestMD · X

@VivekSubbiah @JAMAOnc @OncoAlert Sad, 7 yrs later we still have no prospective data w/denominators showing benefit; even tho we do it, practice is still driven overwhelmingly by hype, anecdotes, & faith-based bias rather than real evidence. This is what you see in real world: https://t.co/qdAg0mne4B

Mar 19, 2023 · 20 likes · 5 shares · 22,392 followers View post →
Andres F. Cardona
@AndresFCardonaZ · X

RT @StephenVLiu: Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated wit…

Mar 17, 2023 · 8 shares · 8,837 followers View post →
Ana I. Velázquez Mañana, MD, MSc, FASCO
@AnaVManana · X

RT @StephenVLiu: Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated wit…

Mar 17, 2023 · 8 shares · 6,424 followers View post →
Tara Herrmann, PhD
@TaraHerrmannPhD · X

RT @StephenVLiu: Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated wit…

Mar 17, 2023 · 8 shares · 1,971 followers View post →
filippo masini
@filimasini · X

RT @StephenVLiu: Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated wit…

Mar 17, 2023 · 8 shares · 770 followers View post →
Cristina Zannori
@CristinaZ2022 · X

RT @StephenVLiu: Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated wit…

Mar 17, 2023 · 8 shares · 40 followers View post →
Stephen V Liu, MD
@StephenVLiu · X

Real world data on #NTRK in the VA system @JCOPO_ASCO. NTRK fusions in 0.12% of solid tumors sequenced. 12 pts treated with NTRK inhibitors - no responses seen. Included some non-canonical fusions and some did achieve durable SD but disappointing outcomes. https://t.co/B31SCHTzcx

Mar 17, 2023 · 27 likes · 8 shares · 28,673 followers View post →